Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | CASP7 | P55210 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374514 | 1.00 | TLR7 (0.37) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL6809404 | 0.85 | TLR7 (0.33) | TLR7MEN1KMT2ATSHRACHE | |
| SCHEMBL5415222 | 0.83 | CHRNE (0.34) | MEN1KMT2ATSHRACHEMAPK1 | |
| SCHEMBL4298211 | 0.83 | TLR7 (0.36) | TLR7TLR8NUDT1 | |
| SCHEMBL5409950 | 0.81 | NPSR1 (0.37) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL5410638 | 0.79 | TLR7 (0.33) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL6055506 | 0.79 | TLR7 (0.44) | TLR7TLR8NUDT1 | |
| SCHEMBL4301417 | 0.79 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL5413387 | 0.78 | TLR7 (0.41) | TLR7TLR8NUDT1ACHEGAA | |
| SCHEMBL4300725 | 0.77 | TLR7 (0.39) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | claimed |
| US-11633495-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | claimed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3763742-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-10-05 | — | — | EP | claimed |
| CN-109152832-A | Anti-CD 20 for treating tumour combines | 博笛生物科技有限公司 | 2019-01-04 | — | — | CN | claimed |
| US-20190002583-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-01-03 | — | — | US | claimed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | claimed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | claimed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | claimed |
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-04-27 | — | — | US | claimed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | claimed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | claimed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | claimed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885TLR8 585/4885NUDT1 3947/4885 |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | TLR7 1537/4885TLR8 2076/4885NUDT1 1375/4885 |
| US-20190002583-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, FCGR2A, FCER2 | TLR7 309/4885TLR8 427/4885NUDT1 3974/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | TLR7 362/4885TLR8 249/4885NUDT1 4309/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885NUDT1 3504/4885 |
| US-11633495-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | TLR7 198/4885TLR8 159/4885NUDT1 3366/4885 |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | EGFR, ERBB2, ERBB3 | TLR7 634/4885TLR8 518/4885NUDT1 4361/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885TLR8 901/4885NUDT1 4518/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.